Cutaneous T cell lymphoma

Reinhard Dummer(University Hospital of Zurich), Egle Ramelyte(University of Zurich), Connor J. Stonesifer(Columbia University), Pietro Quaglino(Department of Medical Sciences), Julia Scarisbrick(University Hospital of Zurich), Maarten H. Vermeer(Leiden University Medical Center), Larisa J. Geskin(Columbia University Irving Medical Center), Younha Kim(International Institute for Applied Systems Analysis), Cornelis P. Tensen(Leiden University Medical Center)
Nature Reviews Disease Primers
August 26, 2021
10.1038/s41572-021-00296-9
Cited by 170

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
|Nature|2010|1.4k
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
|Blood|2007|1.4k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k